Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives

• Published in: Journal of nanobiotechnology Vol. 19; no. 1; pp. 110 - 18
• Main Authors: Bagherifar, Rafieh, Kiaie, Seyed Hossein, Hatami, Zahra, Ahmadi, Armin, Sadeghnejad, Abdolvahid, Baradaran, Behzad, Jafari, Reza, Javadzadeh, Yousef
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 17.04.2021; BioMed Central; BMC
• Subjects: Antigens; Apoptosis; Biomarkers; Cancer; Cancer therapies; Care and treatment; Chemoimmunotherapy; Chemotherapy; Clinical trials; Cytokines; Cytotoxicity; Drugs; FDA approval; Gating; Health aspects; Immune system; Immunomodulation; Immunotherapy; Lung cancer; Lymphocytes; Melanoma; Metastasis; Methods; Monoclonal antibody; Mutation; Nanoparticles; Patients; Review; Signal transduction; T cell receptors; Tumorigenesis; Iran; Nanoparticles; Chemotherapy; Monoclonal antibody; Cytokines; Chemoimmunotherapy; Immunotherapy
• ISSN: 1477-3155; 1477-3155
• DOI: 10.1186/s12951-021-00861-0

Nowadays, a potent challenge in cancer treatment is considered the lack of efficacious strategy, which has not been able to significantly reduce mortality. Chemoimmunotherapy (CIT) as a promising approach in both for the first-line and relapsed therapy demonstrated particular benefit from two key gating strategies, including chemotherapy and immunotherapy to cancer therapy; therefore, the discernment of their participation and role of potential synergies in CIT approach is determinant. In this study, in addition to balancing the pros and cons of CIT with the challenges of each of two main strategies, the recent advances in the cancer CIT have been discussed. Additionally, immunotherapeutic strategies and the immunomodulation effect induced by chemotherapy, which boosts CIT have been brought up. Finally, harnessing and development of the nanoparticles, which mediated CIT have expatiated in detail.